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Abstract
Setting: The dual epidemics of HIV-TB including MDR-TB are major contributors to high morbidity and mortality rates in
South Africa. Rifampicin (RIF) resistance is regarded as a proxy for MDR-TB. Currently available molecular assays have the
advantage of rapidly detecting resistant strains of MTB, but the GeneXpert does not detect isoniazid (INH) resistance and
the GenoTypeMTBDRplus(LPA) assay may underestimate resistance to INH. Increasing proportions of rifampicin mono-
resistance resistance (RMR) have recently been reported from South Africa and other countries.
Objective: This laboratory based study was conducted at NHLS TB Laboratory, Durban, which is the reference laboratory for
culture and susceptibility testing in KwaZulu-Natal. We retrospectively determined, for the period 2007 to 2009, the
proportion of RMR amongst Mycobacterium tuberculosis (MTB) isolates, that were tested for both RIF and INH, using the gold
standard of culture based phenotypic drug susceptibility testing (DST). Gender and age were also analysed to identify
possible risk factors for RMR.
Design: MTB culture positive sputum samples from 16,748 patients were analysed for susceptibility to RIF and INH during
the period 2007 to 2009. RMR was defined as MTB resistant to RIF and susceptible to INH. For the purposes of this study,
only the first specimen from each patient was included in the analysis.
Results: RMR was observed throughout the study period. The proportion of RMR varied from a low of 7.3% to a high of
10.0% [overall 8.8%]. Overall, males had a 42% increased odds of being RMR as compared to females. In comparison to the
50 plus age group, RMR was 37% more likely to occur in the 25–29 year age category.
Conclusion: We report higher proportions of RMR ranging from 7.3% to 10% [overall 8.8%] than previously reported in the
literature. To avoid misclassification of RMR, detected by the GeneXpert, as MDR-TB, culture based phenotypic DST must be
performed on a second specimen, as recommended by the SA NDOH TB guidelines as well as WHO. We suggest that two
sputum samples should be obtained at the first visit. The second sputum sample should be stored at 4uC. The latter sample
is then readily available for performing additional DST (phenotypic or genotypic) for 2nd lines drugs, resulting in a
decreased waiting period for DST results to become available.
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Introduction
The dual epidemics of HIV and TB including MDR-TB are
major contributors to high morbidity and mortality rates in South
Africa [1,2] KwaZulu-Natal, South Africa has one of the highest
rates of HIV and active Tuberculosis (TB) cases in the world [2,3].
MDR-TB is defined as resistance to both isoniazid (INH) and
rifampicin (RIF), with or without resistance to other anti-
tuberculosis drugs [4]. Unlike most other bacteria, resistance in
Mycobacterium tuberculosis(MTB) develops primarily through muta-
tions in chromosomal genes. These mutations develop spontane-
ously and are sustained in the bacterial population mainly through
selective pressure with inappropriate treatment [5,6]. Resistant
mutants arise at a frequency of 1 in 108 to RIF and 1 in 106 to
INH.
Resistance to RIF is largely attributed to nucleotide substitutions
in an 81-bp core region of the rpoB gene [5–7]. In contrast,
resistance to INH occurs by mutations in several genes, in
particular inhA and katG, and to a lesser extent in ahpC, oxyR, kasA,
furA and ndh [6–8]. Separate mutations are required for drug-
susceptible strains to become multidrug-resistant ie MDR-TB, as
mutations to INH and RIF are not directly linked [7,9,10].
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RIF resistance is regarded as a proxy for MDR-TB as a large
proportion of RIF resistant strains have INH resistance as well
[10–14]. Theoretically, if RIF resistance and MDR-TB were
perfectly correlated, then detection of MDR-TB would be
sufficient with a single rapid test that detects RIF resistance. In
areas with low RMR but high MDR prevalence, this correlation is
particularly applicable. In countries with reports of increasing rates
of RMR, this correlation may be questionable and not always
applicable [15–17].
For the optimal and accurate management of MDR-TB, both a
positive culture of MTB and culture based phenotypic drug
susceptibility testing (DST) is required. However, conventional
methods of culture based phenotypic drug susceptibility testing
(DST) are labour intensive and do not provide rapid results [9,10].
The growing demand for rapid diagnosis has resulted in molecular
techniques being increasingly utilized, not only for the detection of
MTB, but also MDR-TB [9]. Molecular based tests, such as
GenoTypeMTBDRplus assay (LPA) (Hain-Lifescience, Germany),
which tests for both RIF and INH susceptibility, and the more
recently introduced, GeneXpert MTB/RIF assay (Cepheid, USA),
which tests for RIF susceptibility only, are being increasingly used
in developed countries as well asSouth Africa, for the rapid
detection of resistant MTB [9,10].
Although, molecular assays have the advantage of rapidly
detecting resistant strains of MTB, the GeneXpert detects only
RIF resistance, whereas the LPA assay detects resistance to both
RIF and INH, but underestimates resistance to INH [18]. This
underestimation occurs because the LPA detects only a limited
number of INH resistant genes. According to published data, the
accuracy estimates for INH are variable and the sensitivity is
highly heterogeneous across studies, ranging from 57% to 100%
[19].
Due to the limitations of molecular based diagnostics, the
misreporting of RMR as MDR-TB is probable. This may not only
result in falsely elevated rates of MDR-TB being reported,
impacting on surveillance data in particular countries, but may
also impact on optimal management of patients as well. In an era
of total drug resistance and a need for novel anti tuberculosis
drugs, any incorrect use of a particular drug will result in
increasing resistance and therefore it is important to preserve the
drugs we already have.
This study was undertaken in KwaZulu-Natal, South Africa,
which has one of the highest rates of HIV and Tuberculosis (TB)
co-infections in the world. We retrospectively determined the
prevalence of true RIF mono-resistance, using the gold standard of
culture based phenotypic drug susceptibility testing (DST), due to
limitations of the currently available molecular assays.
Materials and Methods
Ethical Considerations
Ethics approval was obtained from the University of KwaZulu-
Natal Biomedical Research Ethics Committee (BREC).
Study Setting
The study was conducted at the National Health Laboratory
Services [NHLS], Provincial TB Reference Laboratory, based at
Inkosi Albert Luthuli Central Hospital (IALCH). All specimens
received were routinely cultured, and if positive on culture,
underwent phenotypic drug susceptibility testing during the period
2007–2009. This laboratory currently performs all culture and
culture based phenotypic drug susceptibility testing (DST)for the
province of KwaZulu-Natal. The laboratory participates in both
international and national external, as well as internal quality
assurance programs.
Study Samples
Sputum samples were initially decontaminated with an equal
volume of N-acetyl-L-cysteine-sodium hydroxide (NALC-NaOH)
and processed using standard laboratory methods. After refriger-
ated centrifugation, the sediment was cultured on mycobacterial
growth indicator tubes (MGIT) with PANTA and OADC (Oleic
Acid Dextrose Catalase) and incubated in the BACTEC MGIT
960 system (BD Diagnostics Systems, Sparks, MD). Middlebrook
7H11 agar plates were also inoculated and incubated at 37uC for
six weeks. Positive cultures were confirmed as MTB complex using
niacin and nitrate and/or Rapid MPT64 antigen assay (Standard
Diagnostics, Korea). Positive and negative controls were included
in all procedures and tests performed.
Culture- based phenotypic DST
Culture- based phenotypic DST against both first and second
line anti-tuberculosis drugs, using the 1% agar proportion method
on Middlebrook 7H10 agar plates, was routinely performed on all
specimens received for MCS that were culture positive for MTBC.
Standard drug concentrations were used: 1 ug/ml rifampicin,
0.2 ug/ml isoniazid, 7.5 ug/ml ethambutol, 2 ug/ml streptomy-
cin, 5 ug/ml kanamycin and 2 ug/ml ofloxacin. After a 3 week
incubation period at 37uC, the drug susceptibility plates were
interpreted using a dissecting microscope. For the purposes of this
study, only susceptibility to RIF and INH were analysed.
Statistical Analysis
A Chi-square test for trend was used to determine whether there
was a significant trend in RIF mono-resistance over time,
categorized by quarter. A logistic regression model was fitted to
RMR to determine whether there was an overall difference
between genders and age groups. The overall model testing the
association between age and RMR adjusted for gender and time
(quarter), while the gender-stratified model adjusted for time
(quarter).
Results
Sixty eight thousand seven hundred and twenty six culture
positive sputum samples for the period 2007 to 2009 were analysed
for RIF susceptibility. Of these, 32.5% were found to be RIF
resistant (22,352 of 68,726 samples tested over this period). RMR
proportions were analysed within this subpopulation, and are
reported in quarterly time periods in the text, figures and tables.
Of these RIF resistant cultures, 21 had missing INH susceptibility
data and were excluded from the analysis, leaving a total of 22,331
RIF resistant cultures from 16,748 patients. For the purposes of
this study, only the first specimen from each patient was included
in the analysis.
Of the 16,748 patients data analysed, 431 had missing gender
data and 1504 patients had missing age data. The overall median
age (IQR) as well as the median age in patients with RMR was 32
(26–40) years respectively. The overall gender distribution was
52.3% females and in patients with RMR, it was 44.9%. Overall,
RMR was detected in 8.8% (1,466) of patients during the study
period, with a range of 7.3% to 10%. There was no significant
trend in RMR over the quarters (2007 to 2009) (p = 0.5240), and
no significant trend was observed in either the male or female
population (p = 0.4773 and p = 0.5658, respectively); however,
overall males had a 42% increased odds of being RMR as
compared to females, after adjusting for age and quarter (Odds
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ratio (OR) 1.42; 93% CI 1.27–1.60; p,0.0001). Table 1 depicts
percentages of RMR measured over quarters between 2007 and
2009.
We grouped ages in the following categories: ,18, 18–24, 25–
29, 30–39, 40–49 and 50+ years and assessed RMR over time.
Those aged 25 to 29 years had a significant increase in RMR over
time (p = 0.0094), in comparison to the 50 plus age group, while
those aged 30 to 39 years had a moderate association for a
decreasing trend over time (p = 0.0554). No trends were observed
in the other age groups.
As shown in Table 2, 25 to 29 year olds were at 37% greater
odds of having RMR, in comparison to 50+ year olds (OR 1.37;
95% CI 1.08–1.73; p = 0.0102). However, in females there
appears to be no significant difference between the age groups
and the significant difference between 25 to 29 and 50+ year olds
is largely driven by the male population. Males aged 25 to 29 years
are at 64% increased odds of having RMR compared to 50+ year
olds (OR 1.64; 95% CI 1.21–2.23; p = 0.0016). Although not
statistically significant, 30 to 39 year olds were at a 27% greater
odds of having RMR compared to 50+ year olds (p = 0.0867.
Discussion
RMR was observed throughout the study period of 2007 to
2009. The proportion of RMR varied from a low of 7.3% to a
high of 10.0%, with an overall proportion of 8.8%. To the best of
our knowledge there is a scarcity of data on resistant TB, and in
particular, RMR from African countries. However, in South
Africa, two studies have shown that RIF mono resistance is not
infrequent.
A study from Cape Town, South Africa by Mukinda et al
showed significantly increasing trends in RMR over a 5 year
period (2004–2008). During this period RMR cases more than
tripled, from 31 cases in 2004 to 98 cases in 2008 [15]. Dramowski
et al also reported that RMR disease is increasingly encountered,
particularly among HIV-infected and HIV-exposed non-infected
children in the Cape province [16].
Table 1. Rifampicin mono-resistance over quarters from 2007 to 2009 overall and by gender.
% RIF mono-resistance [95% confidence interval] (Number RIF mono-resistant/Total RIF resistant)
Year Quarter Overall* Females Males
2007 Q1 7.3% [5.7%–9.0%] (72/982) 7.5% [5.1%–9.9%] (36/480) 7.1% [4.7%–9.4%] (32/452)
Q2 7.5% [6.1%–9.0%] (99/1312) 5.9% [4.1%–7.8%] (38/639) 8.7% [6.5%–11.0%] (54/618)
Q3 9.3% [7.8%–10.8%] (141/1514) 7.4% [5.5%–9.3%] (53/715) 10.8% [8.5%–13.0%] (79/732)
Q4 10.0% [8.4%–11.6%] (142/1419) 7.9% [5.9%–9.9%] (56/706) 12.6% [10.1%–15.1%] (84/668)
2008 Q1 8.1% [6.7%–9.4%] (131/1625) 7.4% [5.5%–9.2%] (57/771) 8.9% [6.9%–10.9%] (69/779)
Q2 9.6% [8.1%–11.1%] (140/1465) 8.2% [6.3%–10.1%] (64/780) 10.3% [7.9%–12.6%] (65/633)
Q3 9.2% [7.7%–10.6%] (133/1452) 5.8% [4.1%–7.5%] (42/728) 12.3% [9.9%–14.8%] (84/682)
Q4 8.8% [7.2%–10.4%] (103/1168) 8.3% [6.0%–10.5%] (48/580) 9.0% [6.6%–11.4%] (49/543)
2009 Q1 8.8% [7.3%–10.2%] (122/1393) 8.3% [6.3%–10.3%] (61/731) 9.2% [7.0%–11.4%] (61/662)
Q2 7.8% [6.4%–9.1%] (117/1502) 7.3% [5.5%–9.1%] (60/822) 8.4% [6.3%–10.5%] (57/680)
Q3 10.0% [8.5%–11.6%] (147/1463) 8.8% [6.8%–10.7%] (69/787) 11.5% [9.1%–13.9%] (78/676)
Q4 8.2% [6.8%–9.6%] (119/1453) 6.4% [4.7%–8.1%] (51/794) 10.3% [8.0%–12.6%] (68/659)
Total 8.8% [8.3%–9.2%] 7.4%[6.9%–8.0%] 10.0% [9.4%–10.7%]
(1466/16748) (635/8533) (780/7784)
*A total of 431 patients had missing gender data.
doi:10.1371/journal.pone.0077712.t001
Table 2. Adjusted logistic regression of being Rifampicin mono-resistant, assessing the effect of age, overall and stratified by
gender.
Age group Overall* Females** Males**
(years) Odds Ratio (95% CI) p-value Odds Ratio (95% CI) p-value Odds Ratio(95% CI) p-value
,18 0.99 (0.72–1.35) 0.9316 0.97 (0.60–1.55) 0.8831 0.98 (0.63–1.51) 0.9156
18–24 1.04 (0.80–1.34) 0.7699 1.14 (0.78–1.68) 0.5005 0.84 (0.58–1.21) 0.3482
25–29 1.37 (1.08–1.73) 0.0102 1.12 (0.77–1.63) 0.5693 1.64 (1.21–2.24) 0.0016
30–39 1.17 (0.94–1.46) 0.1562 1.03 (0.72–1.48) 0.8759 1.27 (0.97–1.68) 0.0867
40–49 1.08 (0.85–1.38) 0.5103 1.18 (0.79–1.75) 0.4181 1.03 (0.76–1.40) 0.8561
50+ 1.00(ref) – 1.00(ref) – 1.00 (ref) –
*Adjusting for gender and quarter.
**Adjusting for quarter.
doi:10.1371/journal.pone.0077712.t002
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Similarly, other parts of the world have also reported that RMR
is not uncommon. Sanders et al reported that levels of drug
resistance in Bujumbura are higher than average for Africa and
most worrying was the appearance of MDR-TB and RMR in new
cases [17]. Traore et al studied a large number of MTB complex
clinical isolates from diverse countries to detect RMR. He
reported a median of 4.6% RMR with the highest prevalence in
Western Europe [20]. Pablos-Mendez et al performed anti-TB
drug resistance surveillance (WHO) in 19 different countries and
reported RMRin all. A median of 1.5% was noted, with the
highest rate of 6.9% being reported from both Thailand and
Dominican Republic [21]. In comparison to the above studies, we
report a higher proportion of RMR.
HIV/TB co-infection occurs commonly in our setting with as
high as 70% of TB infected individuals co-infected with HIV
[2,22]. RMR has previously been correlated with HIV positivity
rates. A survey of TB isolates collected in the United States
between 1993 and 1996 documented RMR of 2.6% in HIV-
positive cases and only 0.2% in HIV-negative cases [23]. Similarly,
Sandman et al in New Yorkshowed a RMR prevalence rate of
1,4%, with 81% of cases being detected in HIV positive patients
[24]. Although we did not have access to data on HIV positivity,
which is a major limitation of this study, it is widely recognised that
KZN has one of the highest HIV prevalence rates in the world.
Therefore, the higher proportion of RMR observed in our study
population is most likely explained by the very high prevalence of
HIV.
RMR linked to rifabutin prophylaxis has previously been
documented in studies from developed countries [25]. Rifabutin
prophylaxis to prevent Mycobacterium avium complexis not currently
practiced in South Africa. The increase in RMR in our study
could possibly be attributed to other factors, such as HIV
associated malabsorption of anti-TB drugs, increased rates of
extra-pulmonary tuberculosis, previous incorrect management of
TB, adherence challenges and antiretroviral and anti-TB drug
interactions [26–28].
In the current study, males were more likely to have RMR.
Incident rates of tuberculosis in South Africa have shown higher
prevalence rates in males than in females This gendered incidence
was associated with health seeking behaviour and occupation [29].
However, to the best of our knowledge, gender as a specific risk
factor for RMR has not previously been documented by others.
Although using age as risk factor is tenous, in this study RMR
was more likely to occur in the 25–29 year age group. It is well
recognised that HIV is more common in this age group and that
RMR is more common in HIV as previously highlighted [26–28].
Our findings however are in contrast to Mukinda et al who
reported RMR higher in .40 year age group [15].
It is important to note that we did not specifically address the
reliability of RIF resistance detected by molecular tests as a proxy
for MDR-TB. Nevertheless, our findings, using culture –based
phenotypic DST as the gold standard, indicate a significant
proportion of RMR ranging from 7.3% to 10% (overall 8.8%) in
KZN, South Africa. If molecular assays are to be more widely
used, it is essential that confirmatory culture based phenotypic
DST, as recommended by WHO, be performed, particularly in
geographical areas with high RMR rates. The South African
National Department of Health TB guidelines also clearly state
that a second sputum specimen must be sent in cases of RIF
resistance detected by GeneXpert. This approach circumvents the
misclassification of RMR as MDR-TB, which is particularly
relevant in countries where RIF resistance, detected by the
GeneXpert, is initially recorded as MDRTB in TB registers.
Regarding the LPA assay, the converse is true, in that it
underestimates INH resistance, and may be erroneously reported
as RMR. The accuracy estimates for INH are variable and the
sensitivity is heterogeneous across studies, ranging from 57% to
100% [19]. In a study carried out in Uganda, the sensitivity,
specificity, positive and negative predictive values were: 80.8%,
100.0%, 100.0% and 93.0% respectively for detection of isoniazid
resistance [30]. A sensitivity, specificity, positive and negative
predictive value of 94.2, 99.7, 99.1, and 97.9% was reported from
a study carried out in South Africa [9].
Currently, culture based phenotypic DST results become
available in 21 days or more under ideal conditions. Results
may further be delayed due to contaminated laboratory cultures,
delays in tracking patients and transfer of patients to different
health facilities. Attending clinicians may therefore not obtain
culture- based phenotypic DST results timeously, and many cases
of RMR will continue to be erroneously classified as MDR-TB.
Furthermore, therapy for RMR-TB has not yet been optimised,
with many cases currently being treated with potentially toxic and
expensive regimens used for MDR-TB [31]. The SA NDOH
recommends that these cases be treated as MDR-TB with the
addition of INH for 18 months [32].
We report a higher proportion of RMR, ranging from 7.3% to
10%, (overall 8.8)] than previously reported in the literature. To
avoid misclassification of RMR, detected by the GeneXpert, as
MDR-TB, culture based phenotypic DST must be performed on a
second specimen, as recommended by the SA NDOH TB
guidelines as well as WHO.
In conclusion, we suggest that two sputum samples should
ideally be obtained at the first visit The second sputum sample
should be stored at 4uC. The latter sample is then readily available
forperforming additional DST (phenotypic or genotypic) for 2nd
line drugs. This will therefore decrease the waiting period for DST
results to become available.
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